Abstract
Oxygen transfer agents have long been sought as a means to treat hypoxia caused by congenital or acquired conditions. Hemoglobin-based oxygen carriers were in clinical development as blood substitutes, but development was halted due to the finding of significant vasoactivity. Rather than develop a blood substitute, a product for indications characterized by hypoxia is in development. PEGylated bovine carboxyhemoglobin (SANGUINATE™) is both a carbon monoxide releasing molecule and an oxygen transfer agent. It is comprised of three functional components that act to inhibit vasoconstriction, reduce inflammation and optimize the delivery of oxygen. SANGUINATE has the potential to reduce or prevent the effects of ischemia by inhibiting vasoconstriction and re-oxygenating tissue. Phase 1 safety trials in healthy volunteers were completed in 2013. SANGUINATE was shown to be safe and well tolerated with no serious adverse effects. Phase Ib studies have been completed in stable patients with Sickle Cell Disease. SANGUINATE has also been administered to two patients under emergency use protocols. Both patients exhibited improved status following treatment with SANGUINATE.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tsai AG, Cabrales P, Manjula BN et al (2006) Dissociation of local nitric oxide concentration and vasoconstriction in the presence of cell-free hemoglobin oxygen carriers. Blood 108(10):3603–3610
Winslow RM (2003) Current status of blood substitute research: towards a new paradigm. J Intern Med 253(5):508–517
Olofsson CI, Gorecki AZ, Dirksen R et al (2011) Evaluation of MP40X for prevention of perioperative hypotension in patients undergoing primary hip arthroplasty with spinal anesthesia: a randomized, double-blind, multicenter study. Anesthesiology 114(5):1048–1063
Carrol J (2013) Sangart goes MIA after burning through $260M-plus on R&D. Fierce Biotech. http://www.fiercebiotech.com/story/sangart-goes-mia-after-burning-through-260m-plus-rd/2013-11-07
Cabrales P (2013) Examining and mitigating acellular hemoglobin vasoactivity. Antioxid Redox Signal 18(17):2329–2341
Sriram K, Tsai AG, Cabrales P et al (2012) PEG-albumin supraplasma expansion is due to increased vessel wall shear stress induced by blood viscosity shear thinning. Am J Physiol Heart Circ Physiol 302(12):H2489–H2497
Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10(21):1451–1458
Sakai H, Masada Y, Takeoka S et al (2002) Characteristics of bovine hemoglobin as a potential source of hemoglobin-vesicles for an artificial oxygen carrier. J Biochem 131(4):611–617
Foresti R (2008) Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med 34:649–658
Klaus JA, Kibler KK, Abuchowski A et al (2010) Early treatment of transient focal cerebral ischemia with bovine PEGylated carboxy hemoglobin transfusion. Artif Cells Blood Substit Immobil Biotechnol 38(5):223–229
Shen X, Rosario R, Zou YS et al (2011) Improvement in angiogenesis and restoration of blood flow in diabetic mice by SANGUINATE™. FASEB J 25:1091.4
Ananthakrishnan R, Li Q, O’Shea KM et al (2013) Carbon monoxide form of PEGylated hemoglobin protects myocardium against ischemia/reperfusion injury in diabetic and normal mice. Artif Cells Nanomed Biotechnol 41(6):428–436
Zhang J, Cao S, Kwansa H et al (2012) Transfusion of hemoglobin-based oxygen carriers in the carboxy state is beneficial during transient focal cerebral ischemia. J Appl Physiol 113(11):1709–1717
Misra H, Lickliter J, Kazo F et al (2014) PEGylated carboxyhemoglobin bovine (SANGUINATE™): results of a phase I clinical trial. Artif Organs 38(8):702–707
Parmar D (2014) A case study of SANGUINATE™ in a patient with a comorbidity due to an underlying hemoglobinopathy. J Sickle Cell Hemoglobinopath 1:2
Alaali Y, Mendez M, Abdelhak T et al (2014) Compassionate use of SANGUINATE™ in acute chest syndrome. J Sickle Cell Hemoglobinopath 1:1
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, New York
About this paper
Cite this paper
Abuchowski, A. (2016). PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients. In: Elwell, C.E., Leung, T.S., Harrison, D.K. (eds) Oxygen Transport to Tissue XXXVII. Advances in Experimental Medicine and Biology, vol 876. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3023-4_58
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3023-4_58
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3022-7
Online ISBN: 978-1-4939-3023-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)